Watch ENGNW. Know when insiders buy.
One email the day a filing lands. Free.
ENGNW
enGene Therapeutics Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$130.4MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jul 31 | — | — | — | −$34M | −$32.5M | — | -0.47 | −$18.9M | $0 | −$18.9M | Sep 8 |
| Q2 2026 · Apr 30 | — | — | — | −$32M | −$30.2M | — | -0.43 | −$30.5M | $98K | −$30.6M | Sep 8 |
| Q1 2026 · Jan 31 | — | — | — | −$31.2M | −$29.8M | — | 0.44 | −$28.9M | $153K | −$29.1M | Sep 8 |
| Q4 2025 · Oct 31derived | — | — | — | −$39.5M | −$37.9M | — | 3.85 | −$25M | $437K | −$25.4M | Dec 22 |
| Q3 2025 · Jul 31 | — | — | — | −$29.9M | −$29M | — | -0.57 | −$25.6M | $704K | −$26.3M | Sep 8 |
| Q2 2025 · Apr 30 | — | — | — | −$27.1M | −$25.8M | — | -0.51 | −$22.9M | $45K | −$23M | Sep 8 |
| Q1 2025 · Jan 31 | — | — | — | −$26.6M | −$24.6M | — | 0.48 | −$25.7M | $299K | −$26M | Sep 8 |
| Q4 2024 · Oct 31derived | — | — | — | −$17.5M | −$15.3M | — | 0.34 | −$19.6M | $238K | −$19.8M | Dec 22 |
| Q3 2024 · Jul 31 | — | — | — | −$16.8M | −$14.1M | — | 0.32 | −$7.2M | $2K | −$7.2M | Sep 11 |
| Q2 2024 · Apr 30 | — | — | — | −$17.3M | −$15M | — | 0.38 | −$14.2M | $179K | −$14.3M | Sep 11 |
| Q1 2024 · Jan 31 | — | — | — | −$10.8M | −$10.7M | — | 0.46 | −$7.4M | $506K | −$7.9M | Sep 11 |
| Q4 2023 · Oct 31derived | — | — | — | −$10.4M | −$82.5M | — | 120.45 | −$6.8M | $138K | −$6.9M | Dec 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Oct 31 | — | — | −$123.2M | −$117.3M | — | 2.29 | −$99.2M | $1.5M | −$100.7M | — | — |
| FY2024 · to Oct 31 | — | — | −$62.3M | −$55.1M | — | 1.46 | −$48.3M | $925K | −$49.2M | — | — |
| FY2023 · to Oct 31 | — | — | −$26.1M | −$99.9M | — | 151.22 | −$24.7M | $318K | −$25.1M | — | $0 |
| FY2022 · to Oct 31 | — | — | −$19.4M | −$24.5M | — | 44.30 | −$17.6M | $153K | −$17.7M | — | — |
Every number comes from enGene Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.